These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 34830949)

  • 1. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
    Biondetti P; Saggiante L; Ierardi AM; Iavarone M; Sangiovanni A; Pesapane F; Fumarola EM; Lampertico P; Carrafiello G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.
    Singh P; Toom S; Avula A; Kumar V; Rahma OE
    J Hepatocell Carcinoma; 2020; 7():11-17. PubMed ID: 32104669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Brandi N; Renzulli M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.
    Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R
    Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.
    Han JW; Yoon SK
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.
    Chen JJ; Jin ZC; Zhong BY; Fan W; Zhang WH; Luo B; Wang YQ; Teng GJ; Zhu HD
    United European Gastroenterol J; 2024 Mar; 12(2):226-239. PubMed ID: 38372444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.
    Dendy MS; Ludwig JM; Stein SM; Kim HS
    Liver Cancer; 2019 Oct; 8(5):326-340. PubMed ID: 31768343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy.
    Xue J; Ni H; Wang F; Xu K; Niu M
    J Interv Med; 2021 Aug; 4(3):105-113. PubMed ID: 34805958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of locoregional therapies in the wake of systemic therapy.
    Palmer DH; Malagari K; Kulik LM
    J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma.
    Bajestani N; Wu G; Hussein A; Makary MS
    Biomedicines; 2024 Jun; 12(7):. PubMed ID: 39062006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status.
    Qian K; Zhang F; Allison SK; Zheng C; Yang X
    J Interv Med; 2021 Feb; 4(1):1-7. PubMed ID: 34805939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma.
    Dalzell CG; Taylor AC; White SB
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
    Liu H; Wang C; Wang R; Cao H; Cao Y; Huang T; Lu Z; Xiao H; Hu M; Wang H; Zhao J
    Chin J Cancer Res; 2024 Apr; 36(2):167-194. PubMed ID: 38751435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.
    Woeste MR; Geller AE; Martin RCG; Polk HC
    Ann Surg Oncol; 2021 Mar; 28(3):1499-1510. PubMed ID: 33393028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-transplant Clinical Outcome.
    Adeniji N; Arjunan V; Prabhakar V; Tulu Z; Kambham N; Ahmed A; Kwo P; Dhanasekaran R
    Clin Transplant; 2020 Dec; 34(12):e14128. PubMed ID: 33098134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Effects of Intra-Arterial Liver-Directed Therapies.
    Karimi A; Yarmohammadi H; Erinjeri JP
    J Vasc Interv Radiol; 2024 Feb; 35(2):178-184. PubMed ID: 38272638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.